Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tamura

Showing results (761-770 of 770) with videos related to

Pageof 77
Sort By:
You have reached the last page of results.This site can display upto 770 results.
Scientia Sinica|August 1, 1980
Large-scale purification of prothoracicotropic hormone of the silkworm (Bombyx mori)H Nagasawa, F Guo, X C Zhong, et al.
Journal of Viral Hepatitis|August 2, 2014
The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1T Oze, N Hiramatsu, T Yakushijin, et al.
Liver|April 1, 1997
Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose studyY Imai, S Kawata, S Tamura, et al.
Journal of Viral Hepatitis|August 15, 2009
Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responsesY Inoue, N Hiramatsu, T Oze, et al.
Journal of Viral Hepatitis|April 11, 2014
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirinN Harada, N Hiramatsu, T Oze, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 1, 1996
[Effect of FUT-187, oral serine protease inhibitor, on inflammation in the gastric remnant]H Shiozaki, M Inoue, S Tamura, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 29, 2020
Multicenter prospective trial of total gastrectomy versus proximal gastrectomy for upper third cT1 gastric cancerMakoto Yamasaki, S Takiguchi, T Omori, et al.
Journal of Viral Hepatitis|June 26, 2009
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirinT Oze, N Hiramatsu, T Yakushijin, et al.
Journal of Viral Hepatitis|June 26, 2009
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirinN Hiramatsu, T Oze, T Yakushijin, et al.
Bioorganic & Medicinal Chemistry Letters|August 10, 2005
Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potencyA Arasappan, F G Njoroge, T-Y Chan, et al.
Pageof 77

Showing results (761-770 of 770) with videos related to

Sort By:
Pageof 77
You have reached the last page of results.This site can display upto 770 results.
Scientia Sinica|August 1, 1980
Large-scale purification of prothoracicotropic hormone of the silkworm (Bombyx mori)H Nagasawa, F Guo, X C Zhong, et al.
Journal of Viral Hepatitis|August 2, 2014
The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1T Oze, N Hiramatsu, T Yakushijin, et al.
Liver|April 1, 1997
Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose studyY Imai, S Kawata, S Tamura, et al.
Journal of Viral Hepatitis|August 15, 2009
Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responsesY Inoue, N Hiramatsu, T Oze, et al.
Journal of Viral Hepatitis|April 11, 2014
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirinN Harada, N Hiramatsu, T Oze, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 1, 1996
[Effect of FUT-187, oral serine protease inhibitor, on inflammation in the gastric remnant]H Shiozaki, M Inoue, S Tamura, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 29, 2020
Multicenter prospective trial of total gastrectomy versus proximal gastrectomy for upper third cT1 gastric cancerMakoto Yamasaki, S Takiguchi, T Omori, et al.
Journal of Viral Hepatitis|June 26, 2009
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirinT Oze, N Hiramatsu, T Yakushijin, et al.
Journal of Viral Hepatitis|June 26, 2009
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirinN Hiramatsu, T Oze, T Yakushijin, et al.
Bioorganic & Medicinal Chemistry Letters|August 10, 2005
Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potencyA Arasappan, F G Njoroge, T-Y Chan, et al.
Pageof 77